Casirivimab
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms[1][2].
Product Specifications
CAS Number
[2415933-42-3]
Product Name Alternative
REGN10933
UNSPSC
12352203
Target
SARS-CoV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/casirivimab.html
Purity
95.0
Solubility
10 mM in DMSO
Smiles
[Casirivimab]
Molecular Weight
(145.24 kDa)
References & Citations
[1]Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD) : National Institute of Child Health and Human Development; 2006–. Casirivimab. 2022 May 15. |[2]Lee Tatham, et al. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. Microbiol Spectr. 2024 Aug 6;12 (8) :e0391623.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6373382-01 0.1 mL
CDC123 (Cell Division Cycle Protein 123 Homolog, Protein D123, HT-1080, PZ32, C10orf7, D123, FLJ13863) (HRP)
Ask
View Details 
MBS6373382-02 5x 0.1 mL
CDC123 (Cell Division Cycle Protein 123 Homolog, Protein D123, HT-1080, PZ32, C10orf7, D123, FLJ13863) (HRP)
Ask
View Details